More recently, another host alloantigen-specific donor-autologous Tr1-enriched cell product containing 9-13% of Tr1 cells, was used to treat children and adults with hematologic malignancies receiving unmanipulated (NCT03198234) or TCRαβ+ T cell and CD19+ B cell depleted (NCT04640987) HSCT from mismatched unrelated or haploidentical donors (162). The gene discussed is CD19; the disease is hematologic disorder.